Akari Therapeutics, Plc (AKTX)
NASDAQ: AKTX · Real-Time Price · USD
9.58
-0.11 (-1.14%)
Jun 30, 2026, 10:33 AM EDT - Market open
Akari Therapeutics, Earnings Call Transcripts
Fiscal Year 2026
-
The ADC platform has expanded with AKTX-102, demonstrating scalability and innovation in targeting challenging antigens like CEACAM5. Key milestones include an IND/CTA filing for AKTX-101 by year-end and initial clinical data within 18 months.
Fiscal Year 2025
-
A novel ADC platform with a unique immuno-oncology payload, PH1, is advancing toward clinical trials, showing strong preclinical efficacy, synergy with checkpoint inhibitors, and favorable safety. The company is actively pursuing partnerships and outlicensing non-core assets to fund oncology growth.